| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,160 | 3,500 | 17:45 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Hypera plans to launch its own 'Ozempic' 90 days after approval | 71 | Valor International | ||
| 05.02. | Votorantim boosts stake in drugmaker Hypera via discounted capital raise | 1 | Valor International | ||
| HYPERA Aktie jetzt für 0€ handeln | |||||
| 06.10.25 | Dividendenbekanntmachungen (06.10.2025) | 6.249 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) COMPANHIA ENERGETICA DE MINAS GERAIS-CEM ... US2044096012 0,0397 USD 0,0338 EUR COMPANHIA ENERGETICA DE MINAS GERAIS-CEM ... US2044098828 0... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,960 | -0,95 % | Pfizer-Finanzchef geht im August | NEW YORK (dpa-AFX) - Pfizer steht vor einem Wechsel im Finanzressort. Wie der US-Pharmakonzern am Donnerstag in New York mitteilte, wird Finanzvorstand Dave Denton sein Amt zum 15. August niederlegen... ► Artikel lesen | |
| GILEAD SCIENCES | 108,48 | +0,63 % | Dividendenbekanntmachungen (15.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2966 EUR AEGON LTD ADR US0076CA1045 0,2468 USD 0,2134 EUR AGROB IMMOBILIEN... ► Artikel lesen | |
| ASTRAZENECA | 154,60 | +2,32 % | JEFFERIES stuft ASTRAZENECA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca mit einem Kursziel von 18000 Pence auf "Buy" belassen. Die Briten seien die einzige europäische Pharmagröße... ► Artikel lesen | |
| TEVA | 27,500 | -2,48 % | Teva Pharmaceutical Industries Ltd: Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome | NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has... ► Artikel lesen | |
| BIOTEST | 33,000 | 0,00 % | Osborne Clarke berät Grifols S.A. bei der Umwandlung der Biotest AG in eine GmbH & Co. KGaA | ||
| DIGICANN VENTURES | 0,006 | +10,00 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SINOPHARM | 1,830 | -1,43 % | SINOPHARM (01099): PROPOSED DISTRIBUTION OF FINAL DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS (UPDATED) | ||
| ORAMED PHARMACEUTICALS | 3,400 | +2,26 % | Oramed Pharmaceuticals to join Russell 2000, 3000 indexes | ||
| WUXI BIOLOGICS | 3,455 | +1,77 % | WUXI BIO (02269): NEXT DAY DISCLOSURE RETURN | ||
| ACHIEVE LIFE SCIENCES | 4,580 | +7,51 % | Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA | CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve... ► Artikel lesen | |
| COSMO | 72,00 | -2,31 % | Cosmo Pharmaceuticals N.V.: Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany | Dublin, Ireland and Heppenheim, Germany--(Newsfile Corp. - June 15, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) ("Cosmo") is pleased to announce the launch of its innovative acne cream Winlevi... ► Artikel lesen | |
| SHANGHAI FOSUN PHARMACEUTICAL | 1,712 | -1,47 % | FOSUN PHARMA (02196): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 | ||
| GEDEON RICHTER | 33,360 | +0,97 % | Gedeon Richter Plc.: Deadline Extended for 2026 Semmelweis-Richter Journalism Award Applications | Following strong interest and numerous requests, the application deadline for the 2026 Semmelweis-Richter Journalism Award has been extended by two weeks. Submissions are now accepted until June 23... ► Artikel lesen | |
| DR REDDYS | 12,000 | +5,26 % | Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO in Select International Markets | Agreement expands access to XACDURO for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 7,180 | -0,07 % | Corbus Pharmaceuticals Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans |